Hyperinsulinemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hyperinsulinemia – Drugs In Development, 2024 report and make more profitable business decisions.
Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue, and frequent hunger. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes insulin secretion inhibiting agents, diet, exercise, and other lifestyle changes.
The Hyperinsulinemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hyperinsulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hyperinsulinemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hyperinsulinemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hyperinsulinemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hyperinsulinemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AmideBioLLC
Avanti Biosciences Inc
Children's Hospital of Philadelphia
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
Hua Medicine Shanghai Ltd
PegBio Co Ltd
Rezolute Inc
Rhythm Pharmaceuticals Inc
Seneb BioSciences Inc
Twist Bioscience Corp
Xeris Biopharma Holdings Inc
Zealand Pharma AS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hyperinsulinemia reports